|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1983-1-19
|
|
pubmed:abstractText |
Four live influenza A/Victoria/75 (H3N2) recombinant virus vaccines were administered intranasally to a total of 50 volunteers who had little or no detectable serum neutralizing antibody. A recombinant with ts-1[E] having a 38 degrees C shut-off temperature caused febrile reactions or systemic reactions or both in 21% of the volunteers, but one with ts-1A2 having a 37 degrees C shut-off temperature caused no illness. Two recombinants prepared with cold-adapted A/Ann Arbor/6/60 caused 9% febrile reactions or systemic reactions or both. Virus shedding occurred in a minority of the 50 volunteers, but 90% developed a serum neutralizing antibody response. Wild-type A/Victoria/75 virus challenge of 34 of the vaccinated volunteers and 12 others who had had prior natural A/Victoria/75 virus infection revealed similar and significant protection when compared with the 96% infection and 68% febrile illness or systemic illness or both observed in 25 unvaccinated volunteers with little or no serum antibody. These results encourage continued efforts toward development of live influenza virus vaccines.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-342317,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-422239,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-422240,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-4541685,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-473592,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-5000515,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-500204,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-521798,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-669818,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-669819,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-6939404,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-695327,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-6997969,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-7007522,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-7387405,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-7462696,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-7462697,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-810557,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7141686-846492
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0019-9567
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
38
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
141-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7141686-Adult,
pubmed-meshheading:7141686-Antibodies, Viral,
pubmed-meshheading:7141686-Drug Evaluation,
pubmed-meshheading:7141686-Humans,
pubmed-meshheading:7141686-Influenza, Human,
pubmed-meshheading:7141686-Influenza A Virus, H3N2 Subtype,
pubmed-meshheading:7141686-Influenza A virus,
pubmed-meshheading:7141686-Influenza Vaccines,
pubmed-meshheading:7141686-Male,
pubmed-meshheading:7141686-Recombination, Genetic,
pubmed-meshheading:7141686-Temperature,
pubmed-meshheading:7141686-Vaccination,
pubmed-meshheading:7141686-Vaccines, Attenuated
|
|
pubmed:year |
1982
|
|
pubmed:articleTitle |
Live influenza A/Victoria/75 (H3N2) virus vaccines: reactogenicity, immunogenicity, and protection against wild-type virus challenge.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Controlled Clinical Trial
|
